Stay away from Ajanta Pharma, Sasken: SP Tulsian

SP Tulsian, sptulsian.com advises traders to stay away from Ajanta Pharma and Sasken.

Tulsian told CNBC-TV18, “Ajanta Pharma has posted very good numbers and they have shown an Earnings Per Share (EPS) of close to Rs 14 for the quarter. I do not know what the status is now, but it was frozen upwards 20 percent. So definitely this is not the time to buy the stock, but in respect to the Sasken there has been no consistency.”
He further added, “One can compare the performance of the Sasken more on the lines of Polaris where they show two good quarters and then they show two bad quarters. So I will definitely remain away from Sasken and also from Ajanta Pharma since it has now frozen at 20 percent upwards. I will not be looking to buy this stock at these levels.”